Senior ManagementOur management team consists of industrial and academic scientists with decades of cumulative experience working on the development of a wide range of compounds at differing stages of development. This translates into expert understanding of practical requirements of preclinical and clinical development, as well as cGMP, the importance of regulatory acceptability of excipients and manufacturing processes. Key Staff
Chris is a University of London graduate and has been with Pharmaterials since 2007. Chris is a senior member of the management team and has helped shape and build Pharmaterials.
Chris brings with him the experience of working in contract organisations and before joining Pharmaterials Chris used to work as a scientist for Reading Scientific Services Ltd (RSSL). He has extensive experience of the contract business both from the scientific side as well as the commercial side. He has been involved in Business Development since 2000 and has held a variety of Business Development positions. Chris believes in working very closely with the clients and has worked on numerous projects for Pharmaterials with a thorough understanding of the science and project management.
Martin is a science graduate from Brunel University London and has been with Pharmaterials since 2008. Along with the Director of Respiratory Drug Development, Martin has been heavily involved in establishing and growing the inhalation business sector at Pharmaterials.
Martin is responsible for the business development and project management team within Pharmaterials.
Prior to joining Pharmaterials, Martin spent 8 years in the API and generic sector in both lab based roles and in business development. Martin has a wide breadth of experience in the contract pharma business from analytical development to commercial activities. Martin has been with Pharmaterials through the various growth cycles and in Q4 2015 was appointed onto the senior management team.
Bruce Lithgow has extensive experience in developing pharmaceuticals and a thorough knowledge of manufacturing he joined Pharmaterials in June 2008 from another contract research organisation, where he had spent 7 years managing groups of scientists providing a wide range of evaluation, formulation development and manufacturing services. These covered injectable products and conventional solid dosage forms, through to multi-particulate, complex modified release, rapid release solid dispersion and lipidic systems.
Bruce also has extensive skills in inhalation formulation and device development and in analysing, formulating and manufacturing poorly soluble drug substances, from his previous positions at other companies and from 10 years at RPR now Sanofi. He has also gained extensive experience in the field of pharmaceutical physical form, salt selection and characterisation and in clinical trial packaging and supply. His extensive knowledge is used widely in supporting the rapid evaluation and progression of client projects though Pharmaterials.
Jason has over 20 years’ experience within the pharmaceutical and related industries working from discovery through solid form design and optimisation, formulation development to regulatory approval. During this time has headed up several research facilities and has studied several hundred different actives ingredients ranging from small molecules to large biopharmaceuticals. He has a wide expertise in polymorphism/solid state characterisation and its impact upon pharmaceutical development. In particular the analysis and characterisation of low levels of polymorphic impurity and surface disorder on api and excipient molecules and their impact upon formulation design.
Jason also has a sound understanding of intellectual property matters and has been involved in many successful patent litigations worldwide. For several years was a Committee member of the Royal Society of Chemistry Thermal methods Group and is frequently invited to present on both chemistry and intellectual property matters at conferences and workshops worldwide.
Bildad has extensive experience in the development and manufacture of inhalation products. He obtained his PhD is from the School of Pharmacy, University of London, where he worked on drug powder and pressurised metered dose inhaler formulations for small and macromolecule delivery to the lungs. Bildad is an inventor and has patented the use of essential oils in inhalation. Bildad has also worked in past for GSK and was involved with GSK’s inhalation portfolio.
Bildad heads the Respiratory Drug Delivery Section within Pharmaterials and is also responsible for Inhalation in Pharmaceutics International managing a small but very focused team of inhalation scientists which is responsible for developing dry powder inhalers (DPIs), pressurised metered dose inhalers (pMDIs), nebuliser and nasal drug delivery formulations.
Nicola Dixon brings with her more than 35 years of experience in analytical of which 20 years were with Roche and 14 years with another contract manufacturer where she was responsible for managing three teams of analysts. Nicola has been involved in pharmaceutical development industry from preclinical to registration and has a vast understanding of Contract Development and Manufacturing Organisations.
Nicola has successfully supervised and planned the analytical requirements of more than 100 contract pharmaceutical development projects, ranging in value up to £1m to achieve client satisfaction.
Nicola studied Chemistry at Queen Elizabeth College, London.